scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1016410494 |
P356 | DOI | 10.1186/AR4383 |
P932 | PMC publication ID | 3978999 |
P698 | PubMed publication ID | 24246100 |
P5875 | ResearchGate publication ID | 258641067 |
P50 | author | Danny Liew | Q38326593 |
Vivek Thakkar | Q56941027 | ||
Peter Nash | Q63367206 | ||
P2093 | author name string | Susanna M Proudman | |
Wendy Stevens | |||
David Prior | |||
Jane Zochling | |||
Mandana Nikpour | |||
Joanne Sahhar | |||
Eli Gabbay | |||
Janet Roddy | |||
Maureen Rischmueller | |||
Peter Youssef | |||
Susan Lester | |||
Jennifer G Walker | |||
P2860 | cites work | Standardisation of the single-breath determination of carbon monoxide uptake in the lung | Q28275504 |
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study | Q30463476 | ||
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial | Q33156379 | ||
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study | Q33834751 | ||
The pathogenesis of systemic sclerosis | Q34150716 | ||
Criteria for the classification of early systemic sclerosis. | Q34317138 | ||
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll | Q34977467 | ||
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In | Q34999923 | ||
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach | Q35552142 | ||
Changes in causes of death in systemic sclerosis, 1972-2002 | Q35954516 | ||
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland | Q37085266 | ||
Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review | Q37424577 | ||
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group | Q37643044 | ||
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee | Q39513167 | ||
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement | Q39641547 | ||
Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. | Q39701731 | ||
Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension | Q40547439 | ||
Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis | Q42969084 | ||
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil | Q43218254 | ||
Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic | Q43838385 | ||
Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies | Q44577909 | ||
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial | Q45069603 | ||
N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers | Q48117072 | ||
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension | Q48550363 | ||
NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy | Q48631855 | ||
Is pulmonary arterial hypertension really a late complication of systemic sclerosis? | Q51131925 | ||
Preliminary criteria for the classification of systemic sclerosis (scleroderma) | Q54165663 | ||
Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival | Q56978019 | ||
The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France | Q56978153 | ||
Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study | Q56978308 | ||
Connective Tissue Disease–associated Pulmonary Arterial Hypertension in the Modern Treatment Era | Q60168168 | ||
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis | Q79782391 | ||
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis | Q80419679 | ||
N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study | Q80428291 | ||
Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization | Q80510899 | ||
Usefulness of echocardiography in the identification of an excessive increase in pulmonary arterial pressure in patients with systemic sclerosis | Q83299938 | ||
Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosis | Q84926020 | ||
P433 | issue | 6 | |
P921 | main subject | arterial hypertension | Q41861 |
brain natriuretic peptide | Q66360952 | ||
P304 | page(s) | R193 | |
P577 | publication date | 2013-01-01 | |
P1433 | published in | Arthritis Research and Therapy | Q15757229 |
P1476 | title | The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study | |
P478 | volume | 15 |
Q35096375 | A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis |
Q48115705 | A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults |
Q38771824 | Biomarkers in Scleroderma: Progressing from Association to Clinical Utility |
Q33582869 | Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. |
Q91948784 | Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline |
Q38271027 | Early detection of pulmonary arterial hypertension |
Q33801248 | High sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center. |
Q50097908 | Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. |
Q90966606 | Major lung complications of systemic sclerosis |
Q40153822 | Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model |
Q30490484 | Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol |
Q38367248 | Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension. |
Q92534334 | Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment |
Q92133612 | Screening strategies for pulmonary arterial hypertension |
Q38663003 | Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases. |
Q36234697 | Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension |
Search more.